
The Latest in Diabetes Drugs: Less Hypoglycemia, More Weight Loss
By Emma Ryan and Payal Marathe
Research presented at EASD 2017 showcased drugs, both new and old, that improve blood sugar management, weight loss, heart health, and even blood pressure
New research presented at the recent European Association for the Study of Diabetes (EASD) conference showed promising results, including lower A1c, better heart health, weight loss, and less hypoglycemia (low blood sugar). Click to read more about the most notable updates on new therapies:
Semaglutide – a once-weekly GLP-1 injection for type 2 diabetes (under FDA review after a very positive Advisory Committee meeting in which four diaTribe Foundation volunteers participated)
Bydureon – a once-weekly GLP-1 injection for type 2 diabetes (available now, with a newly-approved, easier way to take it)
Add-on pills for type 1 – SGLT “class” Farxiga (available now) and sotagliflozin (in development)
Tresiba – a once-daily basal insulin for type 1 and type 2 (available now)
Sulfonylureas versus pioglitazone – type 2 diabetes pills (available now)
Glimepiride versus ertugliflozin – type 2 diabetes pills (available now and in development, respectively)
The EASD meeting also included discussions of much more than diabetes drug therapies. You can read diaTribe’s coverage of a study showing improved outcomes from CGM use during pregnancy and The diaTribe Foundation’s event on “Solvable Problems in Diabetes.”
Semaglutide– a once-weekly injection for type 2 diabetes (under FDA review)
Researchers presented new weight loss data on semaglutide, a once-weekly GLP-1 agonist that is c
Continue
reading